Citations (62)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (20)
Peter M. A. Calverley, Alberto de la Hoz, Wenqiong Xue, Gary T. Ferguson & Marc Miravitlles. (2020) COPD Maintenance Therapy with Tiotropium/Olodaterol Compared with Tiotropium: An Analysis in the Absence of Additional ICS Therapy. COPD: Journal of Chronic Obstructive Pulmonary Disease 17:5, pages 477-484.
Read now
Read now
Jean Bourbeau, Mohit Bhutani, Paul Hernandez, Shawn D. Aaron, Meyer Balter, Marie-France Beauchesne, Anthony D’Urzo, Roger Goldstein, Alan Kaplan, François Maltais, Don D. Sin & Darcy D. Marciniuk. (2019) Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD – 2019 update of evidence. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 3:4, pages 210-232.
Read now
Read now
Claudio Micheletto, Fulvio Braido, Marco Contoli, Fabiano Di Marco & Pierachille Santus. (2019) A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 2185-2193.
Read now
Read now
Paola Rogliani, Luigino Calzetta, Maria Gabriella Matera, Nicola di Daniele, Andrea Girolami, Mario Cazzola & Josuel Ora. (2019) Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 20:6, pages 737-750.
Read now
Read now
Evgenios I. Metaxas & Evangelos Balis. (2018) The safety of indacaterol for the treatment of COPD. Expert Opinion on Drug Safety 17:6, pages 637-642.
Read now
Read now
Paola Rogliani, Josuel Ora, Maria Gabriella Matera, Mario Cazzola & Luigino Calzetta. (2018) The safety of dual bronchodilation on cardiovascular serious adverse events in COPD. Expert Opinion on Drug Safety 17:6, pages 589-596.
Read now
Read now
Hideyasu Yamada, Norihito Hida & Nobuyuki Hizawa. (2018) Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 3141-3147.
Read now
Read now
Jean Bourbeau, Mohit Bhutani, Paul Hernandez, Darcy D. Marciniuk, Shawn D. Aaron, Meyer Balter, Marie-France Beauchesne, Anthony D'Urzo, Roger Goldstein, Alan Kaplan, François Maltais, Denis E. O'Donnell & Don D. Sin. (2017) CTS position statement: Pharmacotherapy in patients with COPD—An update. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 1:4, pages 222-241.
Read now
Read now
Dave Singh, Massimo Corradi, Monica Spinola, Alberto Papi, Omar S Usmani, Mario Scuri, Stefano Petruzzelli & Jørgen Vestbo. (2017) Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 2917-2928.
Read now
Read now
Mike Thomas, David MG Halpin & Marc Miravitlles. (2017) When is dual bronchodilation indicated in COPD?. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 2291-2305.
Read now
Read now
Timothy E Albertson, Richart Harper, Susan Murin & Christian Sandrock. (2015) Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol. Patient Preference and Adherence 9, pages 235-242.
Read now
Read now
Charlotte Suppli Ulrik. (2015) Once-daily glycopyrronium bromide (Seebri Breezhaler®) for the treatment of chronic obstructive pulmonary disease (COPD). Expert Opinion on Pharmacotherapy 16:17, pages 2653-2659.
Read now
Read now
Saiprasad Narsingam, Andrew L. Bozarth & Asem Abdeljalil. (2015) Updates in the management of stable chronic obstructive pulmonary disease. Postgraduate Medicine 127:7, pages 758-770.
Read now
Read now
Andrea S Melani. (2015) Long-acting muscarinic antagonists. Expert Review of Clinical Pharmacology 8:4, pages 479-501.
Read now
Read now
Igor Z Barjaktarevic, Anthony F Arredondo & Christopher B Cooper. (2015) Positioning new pharmacotherapies for COPD. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 1427-1442.
Read now
Read now
Nobuyuki Horita & Takeshi Kaneko. (2015) Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 813-822.
Read now
Read now
Andrea Rossi, Erika Zanardi, Venerino Poletti & Mario Cazzola. (2015) Clinical role of dual bronchodilation with an indacaterol–glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 1383-1392.
Read now
Read now
Maria Gabriella Matera, Paola Rogliani & Mario Cazzola. (2015) QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 16:7, pages 1079-1090.
Read now
Read now
Gian Galeazzo Riario-Sforza, Erminia Ridolo, Edoardo Riario-Sforza & Cristoforo Incorvaia. (2015) Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine 9:1, pages 23-33.
Read now
Read now
Maria Gabriella Matera, Paola Rogliani & Mario Cazzola. (2015) Indacaterol for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 16:1, pages 107-115.
Read now
Read now
Articles from other publishers (42)
Mingjin Yang, Yishi Li, Youfan Jiang, Shuliang Guo, Jian-Qing He & Don D. Sin. (2023) Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis. European Respiratory Journal 61:2, pages 2200302.
Crossref
Crossref
Afisi S. Ismaila, Katrin Haeussler, Alexandrosz Czira, Vanita Tongbram, Mia Malmenäs, Jatin Agarwal, Maria Nassim, Marija Živković-Gojović, Yunrong Shen, Xinzhe Dong, Maria Duarte, Chris Compton, Claus F. Vogelmeier & David M. G. Halpin. (2022) Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis. Advances in Therapy 39:11, pages 4961-5010.
Crossref
Crossref
A. G. Chuchalin, S. N. Avdeev, Z. R. Aisanov, A. S. Belevskiy, I. V. Leshchenko, S. I. OvcharenkoE. I. Shmelev. (2022) Federal guidelines on diagnosis and treatment of chronic obstructive pulmonary disease. PULMONOLOGIYA 32:3, pages 356-392.
Crossref
Crossref
Chihiro Kato, Dong Wang, Noriko Nakamura, Takayoshi Sasajima & Hajime Yoshisue. (2022) Real-World Safety and Efficacy of Glycopyrronium Bromide in Japanese Patients with COPD: A 52-Week Post-Marketing Surveillance. The Open Respiratory Medicine Journal 16:1.
Crossref
Crossref
V. I. Kupaev & D. A. Osipov. (2021) Which bronchodilator to choose if a patient with chronic obstructive pulmonary disease continues to smoke?. PULMONOLOGIYA 31:4, pages 469-476.
Crossref
Crossref
Parthasarathi Bhattacharyya, Dipanjan Saha, Sayoni Sengupta & Debkanya De. (2021) Feasibility of testing bronchodilator responsiveness with glycopyrronium in obstructive airway diseases: the initial appraisal of the pilot experience. The Journal of Association of Chest Physicians 9:1, pages 16.
Crossref
Crossref
Manoj J. Mammen, Vandana Pai, Shawn D. Aaron, Linda Nici, Waleed Alhazzani & Paul E. Alexander. (2020) Dual LABA/LAMA Therapy versus LABA or LAMA Monotherapy for Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis in Support of the American Thoracic Society Clinical Practice Guideline. Annals of the American Thoracic Society 17:9, pages 1133-1143.
Crossref
Crossref
Roland Buhl, Dave Singh, Alberto de la Hoz, Wenqiong Xue & Gary T. Ferguson. (2020) Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO® and OTEMTO® Studies. Advances in Therapy 37:8, pages 3485-3499.
Crossref
Crossref
Vitalii I. Kupaev & Dmitriy A. Osipov. (2020) Elderly age group patients with COPD continuing to smoke -a problem that cannot be ignored. Medicine in Drug Discovery 6, pages 100022.
Crossref
Crossref
Linda Nici, Manoj J. Mammen, Edward Charbek, Paul E. Alexander, David H. Au, Cynthia M. Boyd, Gerard J. Criner, Gavin C. Donaldson, Michael Dreher, Vincent S. Fan, Andrea S. Gershon, MeiLan K. Han, Jerry A. Krishnan, Fernando J. Martinez, Paula M. Meek, Michael Morgan, Michael I. Polkey, Milo A. Puhan, Mohsen Sadatsafavi, Don D. Sin, George R. Washko, Jadwiga A. Wedzicha & Shawn D. Aaron. (2020) Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine 201:9, pages e56-e69.
Crossref
Crossref
Ioanna Tsiligianni & Janwillem W. H. Kocks. (2020) Daytime symptoms of chronic obstructive pulmonary disease: a systematic review. npj Primary Care Respiratory Medicine 30:1.
Crossref
Crossref
Usman Maqsood, Terence N Ho, Karen Palmer, Fiona JR Eccles, Mohammed Munavvar, Ran Wang, Iain Crossingham & David JW Evans. (2019) Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2019:3.
Crossref
Crossref
Mitsuhiro Yamada & Masakazu Ichinose. (2018) The Cholinergic Pathways in Inflammation: A Potential Pharmacotherapeutic Target for COPD. Frontiers in Pharmacology 9.
Crossref
Crossref
Yuji Oba, Edna Keeney, Namratta Ghatehorde & Sofia Dias. (2018) Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2018:12.
Crossref
Crossref
Yomna A. Salem, Mohammed E.A. Hammouda, Noha M. Saleh, Mohamed A. Abu El-Enin & Saadia M. El-Ashry. (2018) Validated ion pair chromatographic method for simultaneous determination and in vitro dissolution studies of indacaterol and glycopyrronium from inhaled capsule dosage form. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 204, pages 464-474.
Crossref
Crossref
V. V. Arkhipov. (2018) Prevention of copd exacerbations. Focus on dual bronchodilators. Medical Council:15, pages 8-17.
Crossref
Crossref
Natalia V. Sharova, D. V. Cherkashin, C. L. Grishaev, G. G. Kutelev & A. V. Chumakov. (2018) The values of the modified
bronchodilation test glycopyrronium to identify the reversibility of bronchial obstruction in patients with chronic obstructive pulmonary disease.. Clinical Medicine (Russian Journal) 96:2, pages 158-163.
Crossref
Crossref
James F. Donohue, Paul W. Jones, Christian Bartels, Jessica Marvel, Peter D'Andrea, Donald Banerji, David G. Morris, Francesco Patalano & Robert Fogel. (2018) Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease. Pulmonary Pharmacology & Therapeutics 49, pages 11-19.
Crossref
Crossref
Sahar Zayed & Fathalla Belal. (2017) Rapid simultaneous determination of indacaterol maleate and glycopyrronium bromide in inhaler capsules using a validated stability-indicating monolithic LC method. Chemistry Central Journal 11:1.
Crossref
Crossref
Joerg Salomon, Daiana Stolz, Guido Domenighetti, Jean-Georges Frey, Alexander J. Turk, Andrea Azzola, Thomas Sigrist, Jean-William Fitting, Ulrich Schmidt, Thomas Geiser, Corinne Wild, Konstantinos Kostikas, Andreas Clemens & Martin Brutsche. (2017) Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study. Respiratory Research 18:1.
Crossref
Crossref
Joachim H. Ficker, Klaus F. Rabe & Tobias Welte. (2017) Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium. Pulmonary Pharmacology & Therapeutics 45, pages 19-33.
Crossref
Crossref
Kai M. Beeh, Pierre-Regis Burgel, Frits M. E. Franssen, Jose Luis Lopez-Campos, Stelios Loukides, John R. Hurst, Matjaž Fležar, Charlotte Suppli Ulrik, Fabiano Di Marco, Daiana Stolz, Arschang Valipour, Brian Casserly, Björn Ställberg, Konstantinos Kostikas & Jadwiga A. Wedzicha. (2017) How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?. American Journal of Respiratory and Critical Care Medicine 196:2, pages 139-149.
Crossref
Crossref
Luigino Calzetta, Paola Rogliani, Josuel Ora, Ermanno Puxeddu, Mario Cazzola & Maria Gabriella Matera. (2017) LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. European Respiratory Review 26:143, pages 160043.
Crossref
Crossref
Waleed M. El-Sorougi & Dina Abouelwafa. (2017) INFLOW study: a prospective observational study for assessment of indacaterol and other bronchodilators in symptomatic chronic obstructive pulmonary disease patients from Egypt. Egyptian Journal of Bronchology 11:1, pages 16-22.
Crossref
Crossref
Fabio Arpinelli, Mauro Carone, Gioacchino Riccardo & Giorgio Bertolotti. (2016) Health-related quality of life measurement in asthma and chronic obstructive pulmonary disease: review of the 2009-2014 literature. Multidisciplinary Respiratory Medicine 11:1.
Crossref
Crossref
Michael H. Chiu, Nawaf S. Al-Majed, Ryan Stubbins, Dylan Pollmann & Roopinder K. Sandhu. (2016) A case report of QT prolongation with glycopyrronium bromide in a patient with chronic tamoxifen use. BMC Research Notes 9:1.
Crossref
Crossref
Kazuhisa Asai, Kazuto Hirata, Shu Hashimoto, Yoshinosuke Fukuchi, Tetsuji Kitawaki, Kimitoshi Ikeda, Robert Fogel & Donald Banerji. (2016) Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: Pooled analysis of SHINE and ARISE. Respiratory Investigation 54:6, pages 428-435.
Crossref
Crossref
Luigino Calzetta, Paola Rogliani, Maria Gabriella Matera & Mario Cazzola. (2016) A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. Chest 149:5, pages 1181-1196.
Crossref
Crossref
Marc Miravitlles, Claus Vogelmeier, Nicolas Roche, David Halpin, João Cardoso, Alexander G. Chuchalin, Hannu Kankaanranta, Thomas Sandström, Paweł Śliwiński, Jaromir Zatloukal & Francesco Blasi. (2016) A review of national guidelines for management of COPD in Europe. European Respiratory Journal 47:2, pages 625-637.
Crossref
Crossref
Mario Cazzola & Maria Gabriella Matera. 2017. Pharmacology and Therapeutics of Asthma and COPD. Pharmacology and Therapeutics of Asthma and COPD
117
129
.
Mitsuhiro Yamada & Masakazu Ichinose. (2015) Cutting edge of COPD therapy: current pharmacological therapy and future direction. COPD Research and Practice 1:1.
Crossref
Crossref
Claudio Ferri. (2015) Strategies for Reducing the Risk of Cardiovascular Disease in Patients with Chronic Obstructive Pulmonary Disease. High Blood Pressure & Cardiovascular Prevention 22:2, pages 103-111.
Crossref
Crossref
M. Patout & A. Cuvelier. (2015) Les anticholinergique dans la BPCO et l'asthme. Revue des Maladies Respiratoires Actualités 7:2, pages 187-193.
Crossref
Crossref
Erminia Ridolo, Marcello Montagni, Gian Galeazzo Riario-Sforza, Marco Baroni & Cristoforo Incorvaia. (2015) Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety. Therapeutic Advances in Respiratory Disease 9:2, pages 49-55.
Crossref
Crossref
Hannu Kankaanranta, Terttu Harju, Maritta Kilpeläinen, Witold Mazur, Juho T. Lehto, Milla Katajisto, Timo Peisa, Tuula Meinander & Lauri Lehtimäki. (2015) Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines. Basic & Clinical Pharmacology & Toxicology 116:4, pages 291-307.
Crossref
Crossref
Adolfo Baloira Villar & Marta Núñez Fernández. (2015) La excepción no confirma la regla: lecciones de la física. Archivos de Bronconeumología 51:4, pages 161-162.
Crossref
Crossref
Adolfo Baloira Villar & Marta Núñez Fernández. (2015) The Exception does not Prove the Rule: Lessons From Physics. Archivos de Bronconeumología (English Edition) 51:4, pages 161-162.
Crossref
Crossref
Jayan George, Shehnoor Tarique & Gwyneth A. Davies. 2015. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
195
203
.
Marc Miravitlles, Kai-Michael Beeh & Pablo Altman. (2014) Glycopyrronium for chronic obstructive pulmonary disease: evidence and rationale for use from the GLOW trials. Clinical Investigation 4:12, pages 1095-1111.
Crossref
Crossref
Stefano Nardini, Gianna Camiciottoli, Salvatore Locicero, Rosario Maselli, Franco Pasqua, Giovanni Passalacqua, Riccardo Pela, Alberto Pesci, Alfredo Sebastiani & Alessandro Vatrella. (2014) COPD: maximization of bronchodilation. Multidisciplinary Respiratory Medicine 9:1.
Crossref
Crossref
Jadwiga A. Wedzicha, Ronald Dahl, Roland Buhl, Agnes Schubert-Tennigkeit, Hungta Chen, Peter D'Andrea, Robert Fogel & Donald Banerji. (2014) Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respiratory Medicine 108:10, pages 1498-1507.
Crossref
Crossref
Gustavo J. Rodrigo & Vicente Plaza. (2014) Efficacy and Safety of Indacaterol and Glycopyrronium in COPD. Chest 146:2, pages e75.
Crossref
Crossref